These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 9272119)

  • 1. Pharmacokinetics of doxorubicin and epirubicin in mice during chlorpromazine-induced hypothermia.
    Lundgren-Eriksson L; Carlsson A; Eksborg S; Ryd W; Vesanen R; Hultborn R
    Cancer Chemother Pharmacol; 1997; 40(5):419-24. PubMed ID: 9272119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
    D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of low-protein diet on anthracycline pharmacokinetics and cardiotoxicity.
    El-Demerdash E; Ali AA; El-Taher DE; Hamada FM
    J Pharm Pharmacol; 2012 Mar; 64(3):344-52. PubMed ID: 22309266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic and myocardial enzyme profiles of two administration routes of epirubicin in breast cancer patients.
    Yang RX; Ren HX; Zhuang L; Gao CL; Dong C; Luo CX; Wang XN; Feng EF; He JC
    Arzneimittelforschung; 2012 Dec; 62(12):677-81. PubMed ID: 23203544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
    Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radio-and chemotoxicity in mice during hypothermia.
    Lundgren-Eriksson L; Palm A; Ryd W; Warnhammar E; Hultborn R
    Anticancer Res; 2001; 21(5):3269-74. PubMed ID: 11848482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
    Lo YL; Liu Y; Tsai JC
    Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of micronucleated erythrocytes in mouse bone-marrow under conditions of hypothermia is not associated with stimulation of erythropoiesis.
    Guzmán A; García C; Marín AP; Tortajada A; Ruiz MT; Fernández de Henestrosa AR; Marcos R
    Mutat Res; 2008 Oct; 656(1-2):8-13. PubMed ID: 18718553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protection against doxorubicin toxicity in mice by chlorpromazine hypothermia.
    Gailis L
    Res Commun Chem Pathol Pharmacol; 1986 Sep; 53(3):319-30. PubMed ID: 3775102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs.
    Danesi R; Fogli S; Gennari A; Conte P; Del Tacca M
    Clin Pharmacokinet; 2002; 41(6):431-44. PubMed ID: 12074691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres.
    Sottani C; Poggi G; Quaretti P; Regazzi M; Montagna B; Quaquarini E; Imbriani M; Leoni E; Di Cesare P; Riccardi A; Bernardo G; Minoia C
    Anticancer Res; 2012 May; 32(5):1769-74. PubMed ID: 22593459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of anthracyclines.
    Eksborg S
    Acta Oncol; 1989; 28(6):873-6. PubMed ID: 2611038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of acute hepatic failure on epirubicin pharmacokinetics after intrahepatic arterial injection in rats.
    Nagata M; Matsuo Y; Hidaka M; Kawano Y; Okumura M; Tokunaga J; Takamura N; Arimori K
    Biol Pharm Bull; 2008 Mar; 31(3):493-6. PubMed ID: 18310916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
    Gilbert CM; Filippich LJ; McGeary RP; Charles BG
    Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
    Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
    Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.